Case Report

The Identification and Stereochemistry Analysis of a Novel Mutation p.(D367Tfs*61) in the CYP1B1 Gene: A Case Report

Ahmad Reza Salehi Chaleshtori1, Masoud Garshasbi1, Ali Salehi2, Mehrdad Noruzinia1
1Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, 2Department of Ophthalmology, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Purpose: To investigate the presence of a probable genetic defect(s) that may cause primary congenital glaucoma (PCG) in a seven-year-old female patient.

Methods: A seven-year-old female patient and her family received genetic counseling and underwent full clinical examinations by an expert ophthalmologist. The patient’s genomic DNA was subjected to the targeted gene capture and next-generation sequencing (NGS) along with Sanger sequencing method. The 3D structure prediction and stereochemistry analysis were performed for both mutant and wild-type forms of the CYP1B1 protein.

Results: The clinical examinations indicated that the diagnosis of PCG was correctly made. We identified a novel homozygous deletion in which a ‘C’ nucleotide was deleted from the final exon of the Cytochrome P450 Family 1 Subfamily B Member 1 (CYP1B1) gene. The 3D molecular modeling of the CYP1B1 protein predicted significant structural changes could occur in this protein as a result of the mutation mentioned earlier. The stereochemistry analysis revealed mutant features of the protein, as well as significant misfolding and possible malfunctions in the mutant form of the CYP1B1 protein.

Conclusions: This mutation might cause a frameshift in the translation process, leading to the malfunction of the CYP1B1 protein and development of glaucoma. This newly-identified mutation could be regarded as potential deletion mutation in genetic counseling and molecular examination for the detection of PCG disease in Iran.

Keywords: Cytochrome P450 family 1 subfamily B member 1, CYP1B1, Deletion mutation, Iran, Primary congenital glaucoma

INTRODUCTION

Congenital glaucoma (CG) is the most common form of infantile glaucoma, also known as primary congenital glaucoma (PCG).1 The disease occurs in one of every 27,800 live births in Europe, and 70–80% of cases are classified as bilateral glaucoma (www.orpha.net). The diagnosis of PCG is made according to the predefined clinical criteria, including elevated intraocular pressure (IOP) in a child (especially in the first year of life), enlargement of the globe (buphthalmos), increased corneal diameter, cloudy corneas, cracks in Descemet’s membrane, thinning of the anterior sclera and iris atrophy, photophobia, excessive tearing, anomalously deep anterior chamber, and structurally normal posterior segment except for progressive glaucomatous optic atrophy.2-4 Most cases of PCG are sporadic, but 40% of cases are inherited in...
an autosomal recessive manner with incomplete penetrance. To date, five loci have been identified to be associated with PCG, namely: GLC3A (2p22.2),6,7 GLC3B (1p36), GLC3C (14q24.3),8 GLC3D (14q24),10 and GLC3E (9p21.2).11 Mutations that occur in the Cytochrome P450 Family 1 Subfamily B Member 1 (CYP1B1) gene explain most PCG cases, and its mutations mainly exhibit variable expressivity rather than nonpenetration.12 Approximately, 70% of PCG cases diagnosed in the Iranian population stem from mutations in the CYP1B1 gene,13 while more than 130 pathogenic mutations have been so far characterized, showing that different ethnic groups are prone to develop PCG (http://www.hgmd.cf.ac.uk/ac/index.php). This gene encodes Cytochrome P450 B1 (CYP1B1), a polycyclic aromatic hydrocarbon (PAH) protein that metabolizes Cytochrome P450 (CYP).14 In this study, we identified a single base pair deletion in exon 3 of the CYP1B1 gene in an Iranian female patient with PCG. We also evaluated the potential consequences of the mutation in the resultant protein encoded by the CYP1B1 gene to predict its anomalous effects on the protein structure, function, and disease development.

**CASE REPORT**

A seven-year-old female patient with clinical manifestations of PCG referred to us [Table 1] to receive genetic counseling and molecular testing. The subject was born of consanguineous marriage [Figure 1a]. All family members received genetic counseling, and informed consent was obtained from her parents for participation in the study and publishing the results. We conducted the targeted sequence analysis for the genes associated with PCG (ASB10,15,16 CYP1B1,6 FOXC1,17 LTBP2,18 TEK,19 MYOC,19 NTF4,20 OPAL,21 OPTN,22 TBK1,23 and WDR3624,25). Accordingly, we identified a homozygous single base pair deletion in exon 3 of the CYP1B1 gene in reverse strand of genomic position as follows:

```
(chr2:38298398_38298398delC) (NM_000104(CYP1B1):c.1099_1099delG), p.(D367Thrfs*61) [Figure 1b].
```

This variant is theoretically predicted as a disease-causing factor by Sorting Intolerant From Tolerant (SIFT) (https://sift.biocenter.helsinki. Finland), Protein Variation Effect Analyzer (PROVEAN) (http://provean.jcvi.org/index.php), and MutationTaster (http://www.mutationtaster.org/) software and classified as very strong pathogenic (PVS1) null variant according to the ACMG guidelines and standards.26 This variant is also absent from the 1000 genomes (http://browser.1000genomes.org/index.html), ExAC browser (http://exac.broadinstitute.org/), Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/), and Iranome databases (http://www.Iranome.com/). This deletion variant may lead to a frameshift in the translation process, causing the conversion of an amino acid at the position of 367 into the threonine residue. This procedure is probably followed by the emergence of a stop-codon located at 61 codons downstream of the mutation position p.(Asp367Thrfs*61). The Sanger sequencing and segregation analysis confirmed homozygosity of the variant in the patient, while her parents were heterozygote [Figure 1a and b].

The prediction of the 3D structure of the mutated form of the CYP1B1 protein was conducted by the Phyre 2 web portal (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) and then visualized by the Yet Another Scientific Artificial Reality Application (YASARA) view software (http://www.yasara.org/viewdl.html). The results of the 3D structure prediction for both mutant and wild-type forms of the CYP1B1 protein revealed that some features might be affected in the mutant form of the protein [Figure 2a and b].

It was also demonstrated that several protein features of the mutant form of CYP1B1 would be lost in each output pairwise alignment when compared with its reference alignment [Figure 2c]. These data were consistent with the stereochemistry analysis obtained from the COACH server, COFACTOR server, and PSIPRED workbench [Table 2].

**DISCUSSION**

The female patient who presented the clinical manifestations of PCG was accurately diagnosed with the hierarchical medical diagnosis [Table 1]. The determination of causative mutation(s) seems necessary concerning the prenatal diagnosis (PND) request from her parents; therefore, the targeted sequence analysis was employed for the identification of the gene mutation. We consequently characterized a new homozygous deletion (chr2:38298398_38298398delC) in the CYP1B1 gene which appears to be responsible for the development of PCG [Figure 1a and b].

Homozygous or compound heterozygous mutations that occur in the CYP1B1 gene can cause autosomal recessive PCG, which is assigned to the GLC3A locus. The PCG-associated CYP1B1 gene encodes a mono-oxygenase enzyme, which is a member

| Table 1: Clinical findings of the patient |
|-----------------------------------------|
| **Sing and symptoms**                   |
| IOP (mmHg)                              | 16 |
| Enlargement of globe                    | ++ |
| Increased corneal diameter              | +  |
| Cloudy corneas                          | +  |
| Cracks in Descemet’s membrane           | +  |
| Thinning of the anterior sclera         | +  |
| Iris atrophy                           | -  |
| Photophobia                            | -  |
| Excessive tearing                       | ++ |
| Anomalously deep anterior chamber       | +  |
| Structurally normal posterior segment   | ++ |
| Glaucomatous optic atrophy             | -  |
| Corneal edema                           | ++ |
| Optic nerve exam (cup-to-disc ratio)    | 0.6|
| IOP: Intraocular pressure               |    |

Download the full-text article at Journal of Current Ophthalmology | Volume 32 | Issue 1 | January-March 2020 115
of the CYP superfamily that is in charge of the metabolism and synthesis of cholesterol, steroids, and other lipids.\textsuperscript{27,28} The CYP1B1 gene has been previously reported as a candidate gene for the causation of primary open angle glaucoma (POAG),\textsuperscript{29} while it is considered a leading cause of PCG.\textsuperscript{30} The presence and involvement of GLC3A, GLC3B, GLC3C, GLC3D, and GLC3E loci in PCG indicates the genetic heterogeneity of the disease. The CYP1B1 mutations account for 20–100% of PCG cases in different ethnic groups as 147 various mutations have so far been reported in the CYP1B1 gene.\textsuperscript{30} According to the literature, about 70% of Iranian PCG sufferers are the carriers of four types of CYP1B1 mutations, namely G61E, R368H, R390H, and R469W. These mutations are the most significant mutations which are critical to be checked in Iranian patients with PCG.\textsuperscript{13} This study was in agreement with previous reports, indicating that the CYP1B1 gene is regarded as a high-priority gene in molecular diagnosis of PCG in Iran.\textsuperscript{31}

Our in silico findings were in line with the results obtained from the loss of function (LOF) paradigm, as this variant was considered a disease-causing factor and confirmed by the PROVEAN and MutationTaster tools. Moreover, this deletion variant was also evaluated as a "null" variant according to the American College of Medical Genetics and Genomics (ACMG) standards and guideline.\textsuperscript{26} The Combined Annotation Dependent Depletion (CADD) Phred score was estimated as 25.1 for NM\textunderscore 000104 (CYP1B1):c.1099\textunderscore 1099delG that denotes this variant could be ranked as a rare variant in top 0.1–1% of rare variants. Also, the variant (NM\textunderscore 000104 (CYP1B1):c.1099 1099delG) was absent in the ExAC, 1000G, and Iranome databases. The Iranome database provides suitable ethnicity-matched control groups for this study to consider the variant a mutation with more confidence.

The newly-identified variant is predicted to be functionally incompetent when evaluated by the MutationTaster online

### Table 2: Brief description of stereochemistry analysis results and mutation effects on cytochrome P450 family 1 subfamily B member 1 (CYP1B1) mutant protein

| Services\textsuperscript{a} | Change in cluster size | Change in predicted ligand | Change in consensus binding residues | Protein features |
|------------------------------|------------------------|----------------------------|--------------------------------------|------------------|
| COACH analysis               | +                      | +                          | +                                    | NA               |
| TM site analysis             | +                      | +                          | +                                    | NA               |
| COFACTOR server              | NA                     | NA                         | NA                                   | NA               |
| PSIPRED analysis             | NA                     | NA                         | NA                                   | Loss of six helices, seven strands, and one turn |

\textsuperscript{a}All services are available via Zhang Lab server (https://zhanglab.cemmb.med.umich.edu/). NA: Not applicable
tool (http://www.mutationtaster.org/), while the mutated amino acid is conserved across humans, rhesus monkeys, mice, elephants, and lampreys. However, the amino acid aspartate at the mutation position has been altered in dogs and zebrafish. We postulated that aspartic acid at the position 367 of the CYP1B1 protein has a critical role in the Homo sapiens specie; thus, the modification of aspartic acid at the position 367 can result in the malfunction of the CYP1B1 protein. It has been reported that mutations occurring in the CYP1B1 gene contribute to the development of PCG, and its enzymatic product can produce a signaling molecule, possibly a steroid, that might be involved in eye development. Therefore, the dysfunction of the CYP1B1 protein could lead to the perturbation of vision and eventually blindness. According to the mentioned information, the variant (CYP1B1):c.1099_1099delG might be regarded as a mutation in the CYP1B1 gene. This newly-identified truncating mutation is located in the last exon of the CYP1B1 gene, eliminating more than 10% of the protein sequence and producing a truncated protein [Figure 2c]. Some strand and helix features might be vanished in the mutated form of the protein [Table 2], causing impairment in the functionality of the CYP1B1 protein. The wildtype form of the CYP1B1 protein has a metal-binding domain at the proximity of the 470th amino acid that could be destructed upon p.(Asp367Thrfs*61) mutation. It has been predicted that a group of structural changes can occur in the consensus ligand-binding domain in the mutant form of the CYP1B1 protein when analyzed by the COACH and TM-site tools [Table 2]. Additionally, some modifications predicted emerge in the ligand and ligand-binding site domain when the mutant form of CYP1B1 was compared with the wildtype one via the COFACTOR server [Table 2]. These devastating alterations influence the proper function and interactions of the protein, leading to the interference with eye development and consequently glaucoma.

Moreover, the impairment in the nonsense-mediated mRNA decay (NMD) is another reason for the pathogenesis of PCG in the female patient. These two scenarios provide sufficient evidence for the clinical manifestations of the patient. Recently, a homozygous mutation p.(R368H) has been reported at the next position of the p.(D367Tfs*61) mutation, while its correlation with a reduction of the activity of extradiol metabolism has been proven in patients with PCG. Likewise, in the p.(R368H) mutation, the null activity of retinol metabolism has been previously addressed. As a result, the lowered rate of retinoic acid metabolism is capable of affecting the eye development, and it is considered a pathogenic event concerning the p.(R368H) mutation.

Regarding the information provided above, we concluded that the mutation (NM_000104 (CYP1B1):c.1099_1099delG) is a deletion mutation, this study highlights the significance of the CYP1B1 gene screening in Iranian patients with PCG. The presence of CYP1B1 variants in PCG, POAG, and juvenile open-angle glaucoma (JOAG) have been extensively studied in previous research, and mutations occurring in this gene can lead to the LOF in the CYP1B1 protein as shown in the pathogenesis of PCG. Herein, we reported a newly-identified truncating mutation p.(Asp367Thrfs*61) at a position that is immediately located adjacent to a previously reported pathogenic variant. Therefore, it would be plausible that the same clinical manifestations, observed for the p.(R368H) mutation are expected for this newly-identified mutation. This new variant p.(Asp367Thrfs*61) might be a truncating mutation and could be applied for PND and genetic counseling, especially in Iran.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the legal parents has given her consent for images and other clinical information to be reported in the journal. The parents understands that names and initials will not be published and due efforts will be made to conceal patient identity, but anonymity cannot be guaranteed.

Acknowledgments
The authors would like to thank the patient and her family for their contribution to this study. We also thank Nadia Shojai and Hamid Zahednasab for proofreading the manuscript. This work was supported by Tarbiat Modares University (Grant No. 4923D52).

Conflicts of interest
There are no conflicts of interest.

References
1. Taylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric glaucoma: The Toronto experience. J AAP 1999;3:308-15.
2. Ko F, Papadopoulos M, Khaw PT. Primary congenital glaucoma. Prog Brain Res 2015;221:177-89.
3. Abu-Amero KK, Edward DP. Primary congenital glaucoma. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al., editors. GeneReviews®.Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. Seattle (WA): University of Washington; 1993.
4. Tanwar M, Dada T, Sihota R, Dada R. Mitochondrial DNA analysis in primary congenital glaucoma. Mol Vis 2010;16:518-33.
5. Ho CL, Walton DS. Primary congenital glaucoma: 2004 update. J Pediatr Ophthalmol Strabismus 2004;41:271-88.
6. Sarfarazi M, Akarsu AN, Hossain A, Turacil ME, Aktaq SG, Barsoum-Homsy M, et al. Assignment of a locus (GLC3A) for primary congenital glaucoma (Bupthalmos) to 2p21 and evidence for genetic heterogeneity. Genomics 1995;30:171-7.
7. Morales-Fernandez L, Martinez-de-la-Casa JM, Garcia-Bella J, Mendez C, Saenz-Francs F, Garcia M, et al. Clinical variability of primary congenital glaucoma in a Spanish family with cyp1b1 gene
mutations. J Glaucoma 2015;24:630-4.

8. Akarsu AN, Turaci ME, Aktan SG, Barsoum-Homsy M, Chevrelette L, Sayli BS, et al. A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region. Hum Mol Genet 1996;5:1199-203.

9. Stoilov I, Sarfarazi M. The third genetic locus (GLC3C) for primary congenital glaucoma (PCG) maps to chromosome 14q24. Invest Ophthalmol Vis Sci 2002;43:3015.

10. Sharafeddin, Child AH, Khaw PT, Fleck B, Sarfarazi M. LTBP2 gene analysis in the GLC3C-linked family and 94 CYP1B1-negative cases with primary congenital glaucoma. Ophthalmic Genet 2013;34:14-20.

11. Souma T, Tompson SW, Thomson BR, Siggs OM, Kizhatil K, Yamaguchi S, et al. Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity. J Clin Invest 2016;126:2575-87.

12. Suri F, Yazdani S, Narooie-Nejad M, Zargar SJ, Paylakhi SH, Zeinali S, et al. Variable expressivity and high penetrance of CYP1B1 mutations in primary congenital glaucoma. Ophthalmology 2009;116:2101-9.

13. Chitsazian F, Tusı BK, Eṣahi E, Saroei HA, Sanati MH, Yazdani S, et al. CYP1B1 mutation profile of Iranian primary congenital glaucoma patients and associated haplotypes. J Mol Diagn 2007;9:382-93.

14. Singh AP, Shah PP, Mathur N, Buters JP, Pant MC, Parmar D. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat Res 2008;639:11-9.

15. Wirtz MK, Samples JR, Rust K, Lie J, Nordling L, Schilling K, et al. GLC1F, a new primary open-angle glaucoma locus, maps to 7q35-q36. Arch Ophthalmal 1999;117:2374-81.

16. Pasutto F, Keller KE, Weisschuh N, Sticht H, Samples JR, Yang YF, et al. Variants in ABCB11 are associated with open-angle glaucoma. Hum Mol Genet 2012;21:1336-49.

17. Nishimura DY, Swiderski RE, Alward WL, Searby CR, Patil SR, Bennett SR, et al. The forkhead transcription factor gene FKhL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 1998;19:140-7.

18. Ali M, McKibbin M, Booth A, Parry DA, Jain P, Riazuddin SA, et al. Null mutations in LTBP2 cause primary congenital glaucoma. Am J Hum Genet 2009;84:664-71.

19. Chen Y, Jiang D, Zhang K, Wan B, et al. CYP1B1 and MYOC mutations in 116 Chinese patients with primary congenital glaucoma. Arch Ophthalmol 2008;126:1443-7.

20. Pasutto F, Matsumoto T, Mardin CY, Sticht H, Brandstätter JH, Michels-Rautenstrauss K, et al. Heterozygous NTF4 mutations impairing neurotrophin-4 signaling in patients with primary open-angle glaucoma. Am J Hum Genet 2009;85:447-56.

21. Aung T, Ocaka L, Ebenezer ND, Morris AG, Krawczak M, Thielson DL, et al. A major marker for normal tension glaucoma: Association with polymorphisms in the OPA1 gene. Hum Genet 2002;110:52-6.

22. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077-9.

23. Wang R, Wiggs JL. Common and rare genetic risk factors for glaucoma. Cold Spring Harbor Perspect Med 2014;4:a017244.

24. Moneni S, Spaeth G, DaSilva A, Popinechalk S, Ilichev E, Liebmann J, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet 2005;14:725-33.

25. Pasutto F, Mardin CY, Michels-Rautenstrauss K, Weber BH, Sticht H, Chavarria-Soley G, et al. Profiling of WDR36 missense variants in German patients with glaucoma. Invest Ophthalmol Vis Sci 2008;49:270-4.

26. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.

27. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 1994;269:13092-9.

28. Banerjee A, Chakraborty S, Chakraborty A, Chakraborti S, Ray K. Functional and structural analyses of CYP1B1 variants linked to congenital and adult-onset glaucoma to investigate the molecular basis of these diseases. PLoS One 2016;11:e0156252.

29. Kumar S, Malik MA, Goswami S, Sihota R, Kaur J. Candidate genes involved in the susceptibility of primary open angle glaucoma. Gene 2016;577:119-31.

30. Cascella R, Straffella C, Germani C, Novelli G, Ricci F, Zampatti S, et al. The genetics and the genomics of primary congenital glaucoma. Biomed Res Int 2015;2015:321291.

31. Suri F, Yazdani S, Eṣahi E. Glaucoma in Iran and contributions of studies in Iran to the understanding of the etiology of glaucoma. J Ophthalmic Vis Res 2015;10:68-76.

32. Vasiliou V, Gonzalez FJ. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 2008;48:333-58.

33. Wang A, Savas U, Stout CD, Johnson EF. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem 2011;286:5736-43.

34. Acharya M, Mookherjee S, Bhattacharjee A, Bandyopadhyay AK, Daulat Thakur SK, Bhaduri G, et al. Profiling of WDR36 missense variants in Indian primary open-angle glaucoma (POAG) patients. Mol Vis 2006;12:399-404.

35. Bayat B, Yazdani S, Alavi A, Chiani M, Chitsazian F, Tusı BK, et al. Contributions of MYOC and CYP1B1 mutations to JOAG. Mol Vis 2008;14:508-17.

36. Suri F, Kalhor R, Zargar SJ, Nilforooshan N, Yazdani S, Nezari H, et al. Screening of common CYP1B1 mutations in Iranian POAG patients using a microarray-based PrASE protocol. Mol Vis 2008;14:2349-56.

37. Pasutto F, Chavarria-Soley G, Mardin CY, Michels-Rautenstrauss K, Ingelman-Sundberg M, Fernández-Martínez L, et al. Heterozygous loss-of-function variants in CYP1B1 predispose to primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2010;51:249-54.

38. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2. J Biol Chem 1994;269:13092-9.